Amrita Vishwa Vidyapeetham’s Nanotex Bone Graft Receives Approval for Clinical Trial
Amrita Vishwa Vidyapeetham, a renowned private university, has made a significant breakthrough in the field of medical science. On Thursday, the university announced that it has received approval to conduct a pilot clinical trial for the cutting-edge Nanotex Bone Graft. This revolutionary bone graft was jointly developed by the prestigious Amrita Center for Nanosciences and Molecular Medicine (ACNSMM), Amrita Institute of Medical Sciences (AIMS), and Amrita School of Dentistry (ASD), Kochi.
The Nanotex Bone Graft offers an unprecedented solution to patients who suffer from partial mandibular bone loss due to cancer or traumatic injuries. What sets this product apart is its ability to accept tooth implants, empowering patients to regain a semblance of normalcy in their lives even after losing a portion of their oral cavity bone. The groundbreaking nature of this innovation is further underscored by its status as a world-first product, with a patent to its name.
This notable achievement also marks a historic milestone for the university and the nation. Amrita Vishwa Vidyapeetham proudly claims the distinction of being the first varsity in India to develop its own medical device product and receive approval for conducting an independent clinical trial from the esteemed Central Drugs Standard Control Organization (CDSCO) under the Union Ministry of Health and Family Welfare.
Novel Bone Graft Offers Innovative Solution for Mandibular Bone Loss Due to Cancer or Trauma
The journey from bone graft development to clinical trial approval has been a long and arduous one, spanning nearly a decade. The university attributes this achievement to the unwavering dedication of numerous outstanding students who played pivotal roles in different stages of material development, including design and development, in-vitro studies, small and large animal experiments, regulatory and validation studies, as well as GMP production.
The Nanotex Bone Graft’s potential impact on patients is remarkable. It can be effectively utilized for mandible augmentation, benefitting approximately 50-60 percent of individuals affected by jaw bone cancer. The introduction of this advanced method is not only expected to maintain reasonable treatment costs but also vastly improve the quality of life for those grappling with oral cavity cancers, which account for 10.3 percent of the disease incidence, with 1,35,929 new cases and 8.8 percent mortality.
Amrita Vishwa Vidyapeetham’s Nanotex Bone Graft stands as a testament to the power of relentless research and innovation in transforming medical possibilities. With this groundbreaking product, patients now have renewed hope for a brighter and healthier future.
Also Read:- Max Healthcare and IIT Bombay Join Hands to Drive Healthcare Innovation